Cabotamig Biosimilar Bispecific Antibody (Cadherin-17 × CD3) for Research

Cat No.: GMP-Bios-INN-1118

Anti-CDH17 therapeutic antibody (Pre-made Cabotamig biosimilar,Bispecific (VH-G1CH1h-G4CH2CH3-scFv)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cabotamig (development code ARB202) is a bispecific antibody targeting cadherin 17 (CDH17) and CD3. It is developed by Arbele for gastrointestinal cancers. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1118-1mg 1mg
GMP-Bios-INN-1118-10mg 10mg
GMP-Bios-INN-1118-100mg 100mg
GMP-Bios-INN-1118-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Cabotamig biosimilar, Bispecific (VH-G1CH1h-G4CH2CH3-scFv), Anti-CDH17;CD3E Antibody: Anti-Cadherin-17/CDH17/Intestinal peptide-associated transporter HPT-1/Liver-intestine cadherin (LI-cadherin) therapeutic antibody
INN Name Cabotamig
Target CDH17;CD3E
Format Bispecific (VH-G1CH1h-G4CH2CH3-scFv)
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1/G4;na
VD LC Kappa;Kappa
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Active
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2023
Year Recommended 2024
Companies Arbele
Conditions Approved na
Conditions Active Cholangiocarcinoma;Colorectal cancer;Gastric cancer;Gastrointestinal cancer;Liver cancer;Pancreatic cancer;Biliary cancer
Conditions Discontinued na
Production na
Development Tech na